Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING)

10 agosto 2020 aggiornato da: Shelley Johns, Indiana University

Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING): A Randomized Controlled Pilot Trial for Adults With Metastatic Cancer and Their Family Caregivers

The MEANING trial is a randomized controlled mixed methods pilot designed to compare a novel mindfulness meditation-based intervention (MEANING) to usual care for adults with advanced-stage solid malignancies and their family caregivers.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Mindfulness meditation practices have reduced emotional distress, avoidant coping, and improved spiritual well-being in adult cancer patients. These beneficial effects may occur through present-moment acceptance of unpleasant thoughts, feelings, and circumstances and adaptive coping through self-awareness, self-regulation, and self-transcendence. Most mindfulness trials in cancer have focused on early-stage survivors; however, preliminary evidence suggests that mindfulness may help reduce distress in patients with advanced cancer and their family caregivers (FCGs).

Sixty patients with an advanced-stage solid malignancy and their FCGs (60 dyads) will be randomized in equal numbers to receive either the 6-week mindfulness intervention or usual care. Both groups will receive standard cancer care throughout the study period. Dyads randomized to the mindfulness arm will learn mindfulness meditation practices (e.g., body scan, sitting meditation) and mindful communication practices to enhance quality of life, support advance care planning engagement, and improve a variety of secondary outcomes.

The study will use a mixed methods 2-arm randomized design to examine the effects of the mindfulness intervention compared to usual care and seek to explain trial results using insights gleaned from post-intervention qualitative interviews.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

108

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Stati Uniti
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Indiana University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria-Patients

  • Patient is at least 18 years of age.
  • Patient is at least 3 weeks post-diagnosis of an incurable (locally advanced or metastatic) solid malignancy.
  • Patient's attending medical oncologist would not be surprised if the patient died in the next 12 months.
  • Patient has not completed a POST form.
  • Patient scores ≥ 7 on the Mini-Mental Adjustment to Cancer cognitive avoidance subscale.
  • Patient is willing and able to consent and travel to the class location for 6 weekly 2-hour sessions.
  • Patient has a family member or close friend eligible and interested in participating in the study.
  • Patient has adequate English fluency for completion of data collection

Inclusion Criteria-Family Care Givers (FCG)

  • FCG is at least 18 years of age.
  • FCG has been invited to participate in the trial with a patient who meets eligibility criteria above.
  • FCG is willing and able to consent and travel to the class location for 6 weekly 2-hour sessions.
  • FCG has adequate English fluency for completion of data collection

Exclusion Criteria-Patients

  • Patient reports a score of > 2 on the Activities and Function item from the Patient Generated Subjective Global Assessment91 (PG-SGA; the patient-reported version of the Eastern Cooperative Oncology Group score).
  • Patient makes 3 or more errors on a validated 6-item cognitive screener or exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.
  • Currently receiving hospice care (patients who enroll in hospice during the trial will have the option of continuing trial participation).

Exclusion Criteria-FCGs

• FCG exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Usual Care
Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers. At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
Comparatore attivo: Mindfulness
The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
Comportamentale: Mindfulness
The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from baseline in quality of life (QoL) for Patients
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
QoL for patients will be assessed with the McGill Quality of Life Inventory.
Baseline, 6 weeks, and 10 weeks
Change from baseline in quality of life (QoL) for Family Caregivers
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
QoL for family caregivers will be assessed with the Caregiver Quality of Life - Cancer scale (CQoLC).
Baseline, 6 weeks, and 10 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from baseline in advance care planning (ACP) stage of change
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
ACP stage of change will be assessed by a measure modified from Fried et. al assessing stage of change for 3 advance care planning behaviors (completing a living will, medical power of attorney form, or POLST form; patient only measure).
Baseline, 6 weeks, and 10 weeks
Change from baseline in advance care planning (ACP) engagement
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
ACP engagement (self-efficacy, readiness) will be measured using 2 subscales of the Advance Care Planning Engagement Survey (patient only measure).
Baseline, 6 weeks, and 10 weeks
Change from baseline in caregiver burden
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Caregiver burden will be measured using the Zarit Burden Interview (family caregiver measure only)
Baseline, 6 weeks, and 10 weeks
Change from baseline in avoidant coping
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Avoidant coping will be assessed using the Mini-MAC Cognitive Avoidance subscale
Baseline, 6 weeks, and 10 weeks
Change from baseline in avoidant coping
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Avoidant coping will be assessed using the Brief COPE Self-Distraction, Denial, and Behavioral Disengagement subscales
Baseline, 6 weeks, and 10 weeks
Change from baseline in depressive symptoms
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Depressive symptoms will be assessed using the PHQ-8
Baseline, 6 weeks, and 10 weeks
Change from baseline in anxiety
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Anxiety will be assessed using the GAD-7
Baseline, 6 weeks, and 10 weeks
Change from baseline in spiritual well-being
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Spiritual well-being will be measured using the FACIT-SP.
Baseline, 6 weeks, and 10 weeks
Change from baseline in sleep disturbance
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Sleep disturbance will be assessed using the PROMIS Sleep Disturbance.
Baseline, 6 weeks, and 10 weeks
Change from baseline in family communication
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Family communication will be assessed using the Social Constraint Scale
Baseline, 6 weeks, and 10 weeks
Change from baseline in interpersonal closeness
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Interpersonal closeness will be assessed using the Perceived Interpersonal Closeness Scale.
Baseline, 6 weeks, and 10 weeks
Change from baseline in acceptance of illness
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Acceptance of illness will be assessed using the PEACE Scale.
Baseline, 6 weeks, and 10 weeks
Change from baseline in mindfulness
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Mindfulness will be assessed using the FFMQ-SF Non-reactivity to Internal Experience and Acting with Awareness subscales.
Baseline, 6 weeks, and 10 weeks
Distress Thermometer
Lasso di tempo: Baseline, 6 weeks, and 10 weeks
Distress will be assessed using the Distress Thermometer.
Baseline, 6 weeks, and 10 weeks
Intervention satisfaction and helpfulness
Lasso di tempo: 6 weeks
Satisfaction and helpfulness with the Mindfulness intervention will be assessed using single-item investigator-created 7- and 10-point Likert scales, respectively (Mindfulness group only).
6 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Indiana University

Investigatori

  • Investigatore principale: Shelley A Johns, PsyD, Indiana University School of Medicine

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 maggio 2017

Completamento primario (Effettivo)

11 dicembre 2017

Completamento dello studio (Effettivo)

11 dicembre 2017

Date di iscrizione allo studio

Primo inviato

16 agosto 2017

Primo inviato che soddisfa i criteri di controllo qualità

17 agosto 2017

Primo Inserito (Effettivo)

22 agosto 2017

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 agosto 2020

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 agosto 2020

Ultimo verificato

1 agosto 2020

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 1702223546

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Qualità della vita

Prove cliniche su Mindfulness

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Guatemala

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi